Pegozafermin associated with improved outcomes in nonalcoholic steatohepatitis
1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with ...
Tag: NASH
Intestinal virome signature associated with severity of nonalcoholic fatty liver disease
1. The gut virome among patients with severe NAFLD was found to be different than those with milder NAFLD. #2. ...
2 Minute Medicine Rewind October 14, 2019
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial 1. Adjuvant FOLFOX ...
Quick Take: Pegbelfermin (BMS-986036), a PEGylated Fibroblast Growth Factor 21 Analogue, in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial
Non-alcoholic steatohepatitis (NASH), the most common chronic liver disease in the United States, puts patients at increased risk of developing ...
2 Minute Medicine Rewind December 18, 2018
Pegbelfermin (BMS-986036), a PEGylated Fibroblast Growth Factor 21 Analogue, in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a ...
Health care utilization is higher among patients undergoing liver transplantation for nonalcoholic steatohepatitis (NASH)
Image: CC/Nephron. Histology of NASH Key study points: NASH patients undergoing liver transplant had significantly longer operative times (402 vs. ...
